文献速递瓣膜外科

随机对照试验的Meta分析:经导管与外科主动脉瓣置换术后分期生存比较

Meta-analysis of phase-specific survival after transcatheter versus surgical aortic valve replacement from randomized control trials.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-05-05

该Meta分析纳入8项随机对照试验共8885例平均79岁患者,比较经导管主动脉瓣置换(TAVR)与外科主动脉瓣置换(SAVR)的分期生存。TAVR极短期生存优于SAVR,中期生存低于SAVR,中期心血管死亡和再住院率也偏向SAVR。

要点

  • TAVR极短期(0-1年)生存优于SAVR(HR 0.85,95%CI 0.74-0.98,P=.02)。
  • TAVR中期(2-5年)生存低于SAVR(HR 1.15,95%CI 1.03-1.29,P=.02)。
  • TAVR组主动脉瓣再干预和永久起搏器植入率初期较高,SAVR优势至中期消失。

核心结论

  • 该分析展示了TAVR与SAVR术后分期结局的差异。

研究设计与样本

  • 系统检索数据库从建库至2022年12月,纳入比较TAVR与SAVR结局的随机对照试验。
  • 共纳入8项随机对照试验,总计8885例患者,平均年龄79岁。
  • 分别提取极短期(术后0-1年)、短期(1-2年)和中期(2-5年)的兴趣结局的风险比(HR)及95%置信区间(CI)。
  • 分期HR分别采用随机效应模型合并。

主要发现

  • TAVR与SAVR相比,极短期生存更高(HR 0.85;95%CI 0.74-0.98;P=.02),短期生存相似。
  • TAVR组中期生存低于SAVR组(HR 1.15;95%CI 1.03-1.29;P=.02)。
  • 中期心血管死亡率和再住院率呈现类似的时间趋势,偏向SAVR。
  • TAVR组主动脉瓣再干预率和永久起搏器植入率初期较高,但SAVR的优势至中期消失。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Transcatheter aortic valve replacement (TAVR) is an established alternative to surgical aortic valve replacement (SAVR) for severe symptomatic aortic stenosis, although phase-specific survival and cause of death are implicated following these procedures. Herein, we conducted a phase-specific meta-analysis to compare outcomes after TAVR versus SAVR. METHODS: A systematic search of databases was performed from inception through December 2022 to identify randomized controlled trials that compared outcomes of TAVR and SAVR. For each trial, the hazard ratio (HR) with 95% confidence interval (CI) of outcomes of interest was extracted for the following each specific phase: the very short-term (0-1 years after the procedure), short-term (1-2 years), and mid-term (2-5 years). Phase-specific HRs were separately pooled using the random-effects model. RESULTS: Our analysis included 8 randomized controlled trials, which enrolled a total of 8885 patients with a mean age of 79 years. The survival after TAVR compared with SAVR was greater in the very short-term periods (HR, 0.85; 95% CI, 0.74-0.98; P = .02) but similar in the short-term periods. In contrast, lower survival was observed in the TAVR group compared with the SAVR group in the mid-term periods (HR, 1.15; 95% CI, 1.03-1.29; P = .02). Similar temporal trends favoring SAVR in the mid-term were present for cardiovascular mortality and rehospitalization rates. In contrast, the rates of aortic valve reinterventions and permanent pacemaker implantations were initially greater in the TAVR group, although SAVR's superiority eventually disappeared in the mid-term. CONCLUSIONS: Our analysis demonstrated phase-specific outcomes following TAVR and SAVR.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Yokoyama Y, Shimoda T, Sloan B, et al. Meta-analysis of phase-specific survival after transcatheter versus surgical aortic valve replacement from randomized control trials. J Thorac Cardiovasc Surg. 2023. PMID: 37149212. doi:10.1016/j.jtcvs.2023.04.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。